Literature DB >> 15522741

Vascular endothelial growth factor and its receptors in embryonic zebrafish blood vessel development.

Katsutoshi Goishi1, Michael Klagsbrun.   

Abstract

There is intense interest in how blood vessel development is regulated. A number of vascular growth factors and their receptors have been described. The vascular endothelial growth factor (VEGF) and its receptors are major contributors to normal mammalian vascular development. These receptors include VEGFR-1, VEGFR-2, VEGFR-3, neuropilin-1 (NRP1), and NRP2. The function of these genes have been determined to some degree in mouse gene targeting studies. These knockouts are embryonically lethal, and early death can be attributed in part to lack of normal blood and lymphatic vessel development. More recently, it has been demonstrated that zebrafish are an excellent model for studying the genes and proteins that regulate embryonic vascular development. Zebrafish have a number of advantages compared to mice, including rapid embryonic development and the ability to examine and manipulate embryos outside of the animal. In this review, we describe some of the earlier mouse VEGF/receptor functional studies and emphasize the development of the zebrafish vasculature. We describe the zebrafish vasculature, zebrafish VEGF and VEGF receptors, advantages of the zebrafish model, resources, and methods of determining growth factor and receptor function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15522741     DOI: 10.1016/S0070-2153(04)62005-9

Source DB:  PubMed          Journal:  Curr Top Dev Biol        ISSN: 0070-2153            Impact factor:   4.897


  8 in total

1.  Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization.

Authors:  Harukiyo Kawamura; Xiujuan Li; Katsutoshi Goishi; Laurens A van Meeteren; Lars Jakobsson; Stéphanie Cébe-Suarez; Akio Shimizu; Dan Edholm; Kurt Ballmer-Hofer; Lena Kjellén; Michael Klagsbrun; Lena Claesson-Welsh
Journal:  Blood       Date:  2008-07-29       Impact factor: 22.113

2.  Dihydroartemisinin promotes angiogenesis during the early embryonic development of zebrafish.

Authors:  Qian Ba; Juan Duan; Jia-qiang Tian; Zi-liang Wang; Tao Chen; Xiao-guang Li; Pei-zhan Chen; Song-jie Wu; Li Xiang; Jing-quan Li; Rui-ai Chu; Hui Wang
Journal:  Acta Pharmacol Sin       Date:  2013-05-27       Impact factor: 6.150

3.  Duplicate VegfA genes and orthologues of the KDR receptor tyrosine kinase family mediate vascular development in the zebrafish.

Authors:  Nathan Bahary; Katsutoshi Goishi; Carsten Stuckenholz; Gerhard Weber; Jocelyn Leblanc; Christopher A Schafer; Sarah S Berman; Michael Klagsbrun; Leonard I Zon
Journal:  Blood       Date:  2007-08-14       Impact factor: 22.113

4.  Angiomotin regulates endothelial cell migration during embryonic angiogenesis.

Authors:  Karin Aase; Mira Ernkvist; Lwaki Ebarasi; Lars Jakobsson; Arindam Majumdar; Chunling Yi; Olivier Birot; Yue Ming; Anders Kvanta; Dan Edholm; Pontus Aspenström; Joseph Kissil; Lena Claesson-Welsh; Akihiko Shimono; Lars Holmgren
Journal:  Genes Dev       Date:  2007-08-15       Impact factor: 11.361

5.  GUCA1A mutation causes maculopathy in a five-generation family with a wide spectrum of severity.

Authors:  Xue Chen; Xunlun Sheng; Wenjuan Zhuang; Xiantao Sun; Guohua Liu; Xun Shi; Guofu Huang; Yan Mei; Yingjie Li; Xinyuan Pan; Yani Liu; Zili Li; Qingshun Zhao; Biao Yan; Chen Zhao
Journal:  Genet Med       Date:  2017-01-26       Impact factor: 8.822

6.  Competitive binding between Seryl-tRNA synthetase/YY1 complex and NFKB1 at the distal segment results in differential regulation of human vegfa promoter activity during angiogenesis.

Authors:  Chuan-Yang Fu; Po-Chun Wang; Huai-Jen Tsai
Journal:  Nucleic Acids Res       Date:  2017-03-17       Impact factor: 16.971

7.  Dose-dependent effects of gamma radiation on the early zebrafish development and gene expression.

Authors:  Selma Hurem; Leonardo Martín Martín; Dag Anders Brede; Eystein Skjerve; Rasoul Nourizadeh-Lillabadi; Ole Christian Lind; Terje Christensen; Vidar Berg; Hans-Christian Teien; Brit Salbu; Deborah Helen Oughton; Peter Aleström; Jan Ludvig Lyche
Journal:  PLoS One       Date:  2017-06-19       Impact factor: 3.240

Review 8.  Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma.

Authors:  Vanessa Andrés-Guerrero; Lucía Perucho-González; Julián García-Feijoo; Laura Morales-Fernández; Federico Saenz-Francés; Rocío Herrero-Vanrell; Luis Pablo Júlvez; Vicente Polo Llorens; José María Martínez-de-la-Casa; Anastasios-Georgios Konstas
Journal:  Adv Ther       Date:  2016-12-20       Impact factor: 3.845

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.